Coherus BioSciences/$CHRS
About Coherus BioSciences
Ticker
Industry
Employees
CHRS Metrics
$132M
-
-$0.00
0.69
-
Price and volume
Market cap
$132M
Beta
0.69
52-week high
$2.65
52-week low
$0.66
Average daily volume
2M
Financial strength
Current ratio
2.11
Quick ratio
1.505
Long term debt to equity
-300.671
Total debt to equity
-300.671
Interest coverage (TTM)
-3.63%
Management effectiveness
Return on assets (TTM)
-14.03%
Return on equity (TTM)
0.41%
Valuation
Price to revenue (TTM)
0.429
Price to book
-1.51
Price to tangible book (TTM)
-0.93
Price to free cash flow (TTM)
-2.064
Growth
Revenue change (TTM)
44.19%
Earnings per share change (TTM)
-99.84%
3-year revenue growth (CAGR)
-5.76%
3-year earnings per share growth (CAGR)
-89.17%
What the Analysts think about CHRS
Analyst Ratings
CHRS Financial Performance
Income Statement
Q3 24
QoQ growth
$37B
-39.75%
$45B
107.52%
37.65%
6.78%
CHRS Earnings Performance
Earnings per share (EPS)
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
$3.69
$2.85
$2.45
$2.42
-
$3.55
$2.61
$2.05
$2.31
$3.94
3.94%
9.20%
19.51%
4.63%
-
CHRS News

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development
What’s the current market cap for Coherus BioSciences stock?
What is the P/E ratio for Coherus BioSciences stock?
Does Coherus BioSciences stock pay dividends?
No, Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders as of February 26, 2025.
When is the next Coherus BioSciences dividend payment date?
Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders.
What is the beta indicator for Coherus BioSciences?
Coherus BioSciences (CHRS) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.